Get started
UNITED THERAPEUTICS CORPUNITED THERAPEUTICS CORPUNITED THERAPEUTICS CORP

UNITED THERAPEUTICS CORP

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

UTHR chart


Full chart

UTHR upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪261.53 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
13.65
Basic EPS (TTM)
551.63 MXN
Net income (FY)
‪24.92 B‬ MXN
Revenue (FY)
‪59.99 B‬ MXN
Shares float
‪44.09 M‬
Beta (1Y)
0.63

Employees


Employees (FY)
‪1.3 K‬
Change (1Y)
+137 +11.73%
Revenue / Employee (1Y)
‪45.97 M‬ MXN
Net income / Employee (1Y)
‪19.09 M‬ MXN

About United Therapeutics Corporation


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Martine A. Rothblatt
Website
unither.com
Headquarters
Silver Spring
Founded
1996
FIGI
BBG01LKZR958
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

UTHR news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where UTHR is featured.

See all sparks 


Check out other big names from the same industry as UTHR.

Frequently Asked Questions


The current price of UTHR is 6,583.74 MXN — it hasn't changed in the past 24 hours. Watch UNITED THERAPEUTICS CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange UNITED THERAPEUTICS CORP stocks are traded under the ticker UTHR.
We've gathered analysts' opinions on UNITED THERAPEUTICS CORP future price: according to them, UTHR price has a max estimate of 11,771.40 MXN and a min estimate of 6,160.37 MXN. Watch UTHR chart and read a more detailed UNITED THERAPEUTICS CORP stock forecast: see what analysts think of UNITED THERAPEUTICS CORP and suggest that you do with its stocks.
UTHR reached its all-time high on Feb 19, 2025 with the price of 6,902.22 MXN, and its all-time low was 3,663.34 MXN and was reached on Feb 21, 2024. View more price dynamics on UTHR chart.
See other stocks reaching their highest and lowest prices.
UTHR stock is 0.00% volatile and has beta coefficient of 0.63. Track UNITED THERAPEUTICS CORP stock price on the chart and check out the list of the most volatile stocks — is UNITED THERAPEUTICS CORP there?
Today UNITED THERAPEUTICS CORP has the market capitalization of ‪261.53 B‬, it has decreased by −0.75% over the last week.
Yes, you can track UNITED THERAPEUTICS CORP financials in yearly and quarterly reports right on TradingView.
UNITED THERAPEUTICS CORP is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
UTHR earnings for the last quarter are 129.06 MXN per share, whereas the estimation was 133.43 MXN resulting in a −3.28% surprise. The estimated earnings for the next quarter are 137.19 MXN per share. See more details about UNITED THERAPEUTICS CORP earnings.
UNITED THERAPEUTICS CORP revenue for the last quarter amounts to ‪15.34 B‬ MXN, despite the estimated figure of ‪15.32 B‬ MXN. In the next quarter, revenue is expected to reach ‪14.94 B‬ MXN.
UTHR net income for the last quarter is ‪6.28 B‬ MXN, while the quarter before that showed ‪6.09 B‬ MXN of net income which accounts for 3.14% change. Track more UNITED THERAPEUTICS CORP financial stats to get the full picture.
No, UTHR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 30, 2025, the company has ‪1.3 K‬ employees. See our rating of the largest employees — is UNITED THERAPEUTICS CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UNITED THERAPEUTICS CORP EBITDA is ‪30.22 B‬ MXN, and current EBITDA margin is 50.38%. See more stats in UNITED THERAPEUTICS CORP financial statements.
Like other stocks, UTHR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UNITED THERAPEUTICS CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So UNITED THERAPEUTICS CORP technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating UNITED THERAPEUTICS CORP stock shows the strong buy signal. See more of UNITED THERAPEUTICS CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.